Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
5,225
datasets available to search
ShareScore release 0.9.0
Dataset results
5,225 results for “moderation”
DNA methylation dynamics in Atlantic salmon (Salmo salar) challenged with high temperature and moderate hypoxia
GEO Series GSE153343. Salmo salar. 48 samples. Type: Methylation profiling by high throughput sequencing.
A new syndrome of overgrowth, macrocephaly, hypoglycemia, enlarged ventricles, mild, and moderate intellectual disability and recurrent inflammatory disease is due to mutations in RNF125
GEO Series GSE54335. Homo sapiens. 4 samples. Type: Methylation profiling by array.
Transcriptome analysis using RNA sequencing conducted for wild type (Col-0), ahl10-1 and rrp6l1-2 mutant under control conditions and after 96 h at moderate low water potential (-0.7 MPa)
GEO Series GSE101197. Arabidopsis thaliana. 18 samples. Type: Expression profiling by high throughput sequencing.
Moderate levels of folic acid benefit outcomes for cilia based neural tube defects
GEO Series GSE271941. Mus musculus. 12 samples. Type: Expression profiling by high throughput sequencing.
Integrated biochemical and transcriptomic profiling reveals graded spleen responses to moderate versus severe hypoxia in rainbow trout (Oncorhynchus mykiss)
GEO Series GSE305539. Oncorhynchus mykiss. 9 samples. Type: Expression profiling by high throughput sequencing.
Gene expression of peripheral blood in healthy, moderate asthma, and severe asthma patients from the IMSA cohort
GEO Series GSE207751. Homo sapiens. 56 samples. Type: Expression profiling by high throughput sequencing.
Moderate blast exposure alters gene expression and levels of amyloid precursor protein
GEO Series GSE89866. Homo sapiens. 58 samples. Type: Expression profiling by high throughput sequencing.
Dataset related to article "Safety of Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Viral Hepatitis: A Monocentric Retrospective Study "
<p>This record contains raw data related to article “Safety of Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Viral Hepatitis: A Monocentric Retrospective Study"</p> <p>Abstract</p> <p><strong>Introduction: </strong> There are no strong data regarding the treatment with biologics (especially for the most recent anti-IL-17 and anti-IL-23 drugs) of patients with psoriasis and concomitant viral hepatitis. We assessed the safety of biologic drugs in patients with psoriasis who are seropositive for hepatitis B or C and did not receive antiviral prophylaxis.</p> <p><strong>Methods: </strong> We conducted a retrospective single-center study. The efficacy of biologic treatments was evaluated by assessing the Psoriasis Area and Severity Index (PASI) score during all visits, for a minimum follow-up of 52 weeks. All patients were evaluated by a hepatologist before starting the treatment. They were monitored for reactivation of viral hepatitis.</p> <p><strong>Results: </strong> Twenty patients had positive markers of hepatitis B virus (HBV) or hepatitis C virus (HCV). Seventeen patients had positive markers of HBV infection, and four patients had antibodies for HCV (one patient had serologic evidence of both infections). Anti-IL-23 biologics were the most used in our population, with risankizumab being the most prescribed drug. No patient had evidence of viral reactivation during our study. Study limitations include its retrospective nature and our inclusion of patients with different serological status receiving different biologic drugs.</p> <p><strong>Conclusion: </strong> Biologic therapies (including anti-IL-23 drugs) appear to be safe in patients seropositive for HCV or HBV core antibody who did not receive antiviral prophylaxis.</p>
Dataset related to article "Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study"
<p>This record contains raw data related to article “Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study"</p> <p>Abstract</p> <p><strong>Introduction: </strong> Risankizumab is a humanized monoclonal antibody that selectively targets interleukin-23. It is approved for treatment of moderate-to-severe plaque psoriasis. We conducted a 52-week monocentric retrospective study to evaluate the effectiveness and safety of risankizumab in a real-life setting.</p> <p><strong>Methods: </strong> Our study included 131 adults with moderate-to-severe plaque psoriasis all treated with risankizumab for at least 52 weeks. Patient characteristics and PASI (Psoriasis Area and Severity Index) at each visit were recorded. The percentages of patients achieving 75%/90%/100% (PASI 75/90/100) improvement in PASI with respect to baseline were registered.</p> <p><strong>Results: </strong> At week 52, 93.9%, 78.6%, and 61.1% of patients achieved PASI 75/90/100, respectively. An absolute PASI ≤ 2 was reached by 90.8% at week 52. The higher body mass index and the presence of cardio-metabolic comorbidities did not interfere with the odds of reaching PASI 75/90/100 at each time-point. At week 52, comparable percentages of patients achieved PASI 100, regardless of the involvement of difficult-to-treat-areas. No significant safety findings were recorded and none of the patients had to interrupt the treatment because of adverse events.</p> <p><strong>Conclusions: </strong> Our findings confirmed that risankizumab is a safe and effective therapeutic option for the treatment of a wide "real-life" cohort of patients with psoriasis.</p>
Fig. 2 in Transcriptome and metabolome profiling unveiled mechanisms of tea (Camellia sinensis) quality improvement by moderate drought on pre-harvest shoots
Fig. 2. qRT-PCR verification of 15 selected DEGs. Plot: mean with SD.
TRx0237 for the Treatment of Early and Mild-Moderate Alzheimer's Disease
ClinicalTrials.gov study NCT03539380. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Effect of Ultrasonographic Guided Insulin Injection With Dexamethasone and Local Anesthetic Mixture in Diabetic Patients With Mild to Moderate Carpal Tunnel .
ClinicalTrials.gov study NCT04781777. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Evaluate Artificial Tear Efficacy in Moderate to Severe Dry Eye
ClinicalTrials.gov study NCT00724412. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT)
ClinicalTrials.gov study NCT04705844. IPD Sharing: NO. Countries: 0. Publications: 0.
Ketoprofen 10% Cream for Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury
ClinicalTrials.gov study NCT01223053. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Inhaled Fluticasone Propionate: Effect on Parameters of Bone Metabolism in Patients With Mild to Moderate Asthma
ClinicalTrials.gov study NCT00409630. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Ultrasound Guided Intra Articular Injection of Platelet Rich Fibrin Versus Hyaluronic Acid As Means of Pain Relief in Patients with Moderate Degree Knee Osteoarthritis
ClinicalTrials.gov study NCT06797960. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Physical Activity Moderates Inflammatory Gene Expression in Rheumatoid Arthritis
GEO Series GSE179302. Homo sapiens. 35 samples. Type: Expression profiling by high throughput sequencing.
Preclinical quality, safety and efficacy of a human embryonic stem cell-derived product for treatment of people with moderate Parkinson’s Disease (STEM-PD)
GEO Series GSE229769. Homo sapiens. 9 samples. Type: Genome variation profiling by SNP array; SNP genotyping by SNP array; Other.
Transcriptome analysis using RNA sequencing conducted for wild type (Col-0) and ahl10-1 mutant under control conditions and after 96 h at moderate low water potential (-0.7 MPa)
GEO Series GSE112368. Arabidopsis thaliana. 12 samples. Type: Expression profiling by high throughput sequencing.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.